Cummings, Jeffrey
Montes, Arturo
Kamboj, Sana
Cacho, Jorge Fonseca
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM109025)
National Institute of Neurological Disorders and Stroke (U01NS093334)
National Institute on Aging (R01AG053798)
Article History
Received: 23 December 2021
Accepted: 9 May 2022
First Online: 25 May 2022
Declarations
:
: Not applicable; all data are from a public database that has no participant-level data.
: All authors give consent for publication
: JC has provided consultation to Acadia, Alkahest, AlphaCognition, AriBio, Biogen, Cassava, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Lilly, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Ono, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Signant Health, Suven, and United Neuroscience pharmaceutical, assessment, and investment companies. JC is supported by NIGMS grant P20GM109025, NINDS grant U01NS093334, NIA grant R01AG053798, NIA grant P20AG068053, NIA grant P30AG072959, NIA grant R35AG71476, Alzheimer’s Disease Drug Discovery Foundation (ADDF), Ted and Maria Quirk Endowment, and the Joy Chambers-Grundy Endowment.AM, JF-C, and SK have no competing interests.